Scarica l'app Stockscreener
137.52
0.15%
-0.21
Dopo l'orario di chiusura:
137.52
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
What moving averages say about Neurocrine Biosciences Inc.July 2025 Analyst Calls & Weekly Stock Breakout Alerts - newser.com
Neurocrine Biosciences patents new VMAT2 inhibitors - BioWorld MedTech
Can Neurocrine Biosciences Inc. stock maintain growth trajectory2025 Price Momentum & Risk Managed Trade Strategies - newser.com
Should Neurocrine Biosciences' (NBIX) KINECT-HD2 Data and New Leadership Prompt Investor Action? - simplywall.st
Neurocrine Biosciences Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Does the Recent Rare Earths News Move the Needle for Neurocrine Biosciences Valuation? - simplywall.st
Why Neurocrine Biosciences Inc. stock is trending among retail traders2025 Market WrapUp & Accurate Trade Setup Notifications - newser.com
How risky is Neurocrine Biosciences Inc. stock nowJuly 2025 News Drivers & Intraday High Probability Setup Alerts - newser.com
United States Huntington's Disease Market is expected to reach - openPR.com
Why Neurocrine Biosciences Inc. stock could benefit from AI revolutionMarket Risk Analysis & Growth Focused Stock Reports - newser.com
Is Neurocrine Biosciences Inc a good long term investmentChart Pattern Recognition & Ride the Trends That Billionaires Follow - earlytimes.in
Neurocrine Biosciences (NBIX): Evaluating Valuation Following Recent Clinical Milestones and Leadership Appointment - simplywall.st
Using data models to predict Neurocrine Biosciences Inc. stock movementOil Prices & Weekly Top Gainers Trade List - newser.com
Market reaction to Neurocrine Biosciences Inc.’s recent newsEarnings Performance Report & Daily Oversold Stock Bounce Ideas - newser.com
UBS Group Forecasts Strong Price Appreciation for Neurocrine Biosciences (NASDAQ:NBIX) Stock - MarketBeat
Using economic indicators to assess Neurocrine Biosciences Inc. potential2025 Support & Resistance & Daily Profit Focused Stock Screening - newser.com
Neurocrine Biosciences' (NBIX) "Hold (C+)" Rating Reaffirmed at Weiss Ratings - MarketBeat
How to forecast Neurocrine Biosciences Inc. trends using time seriesJuly 2025 Final Week & Verified Momentum Stock Watchlist - newser.com
Full technical analysis of Neurocrine Biosciences Inc. stockJuly 2025 Recap & Fast Gain Swing Alerts - newser.com
Neurocrine Bio. stock price target raised to $195 from $188 at UBS - Investing.com Nigeria
UBS Raises Neurocrine Biosciences Price Target to $195 From $188, Maintains Buy Rating - MarketScreener
Why Neurocrine Biosciences Inc. (NB3) stock fits value portfoliosQuarterly Trade Summary & Weekly Consistent Profit Watchlists - newser.com
Neurocrine Biosciences publishes positive data from movement disorder study - MSN
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results - cnhinews.com
RBC Lifts Price Target on Neurocrine Biosciences to $156 From $149, Keeps Outperform Rating - MarketScreener
Truist Financial Corp Raises Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Q3 2025 Results: Neurocrine Biosciences to Host Oct. 28 Webcast & Call at 1:30 p.m. PT; Replay 1 Month - Stock Titan
How New Three-Year INGREZZA Data at Neurocrine Biosciences (NBIX) Has Changed Its Investment Story - simplywall.st
A Fresh Look at Neurocrine Biosciences (NBIX) Valuation After Latest INGREZZA Clinical Study Results - Yahoo Finance
Neurocrine Biosciences, Inc. $NBIX Stock Holdings Boosted by QRG Capital Management Inc. - MarketBeat
Earnings call transcript: Neurocrine Q2 2025 shows strong sales growth By Investing.com - Investing.com Australia
Neurocrine Biosciences names Mike Sibley to lead neuropsychiatry franchise By Investing.com - Investing.com Nigeria
Neurocrine reports sustained benefits of INGREZZA for Huntington’s chorea By Investing.com - Investing.com Nigeria
Neurocrine Biosciences names Mike Sibley to lead neuropsychiatry franchise - Investing.com
20+ years commercial leader Mike Sibley named Neurocrine SVP & GM, Neuropsychiatry to lead INGREZZA franchise - Stock Titan
Earnings call transcript: Neurocrine Q2 2025 shows strong sales growth - Investing.com
Is Neurocrine Biosciences Inc. a candidate for recovery playJuly 2025 Update & Low Drawdown Trading Techniques - newser.com
What MACD signals say about Neurocrine Biosciences Inc.Insider Selling & Smart Allocation Stock Tips - newser.com
Intraday pattern recognizer results for Neurocrine Biosciences Inc.2025 Market Overview & Daily Price Action Insights - newser.com
Neurocrine reports sustained benefits of INGREZZA for Huntington’s chorea - Investing.com
Neurocrine shows 3-year safety data for Huntington's drug INGREZZA - StreetInsider
Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea - Prime Publishers, Inc.
Technical signs of recovery in Neurocrine Biosciences Inc.Weekly Market Report & Risk Controlled Daily Trade Plans - newser.com
Will Neurocrine Biosciences Inc. stock deliver consistent dividends2025 Year in Review & Daily Stock Trend Reports - newser.com
What the G7 Rare Earths News Means for Neurocrine Biosciences Valuation in 2025 - simplywall.st
Will Neurocrine Biosciences Inc. benefit from macro trends2025 Short Interest & Real-Time Volume Triggers - newser.com
Will Neurocrine Biosciences Inc. (NB3) stock see valuation expansionEarnings Summary Report & Free Community Consensus Stock Picks - newser.com
5.75%
1.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):